| pubmed-article:2055560 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2055560 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:2055560 | lifeskim:mentions | umls-concept:C0024305 | lld:lifeskim |
| pubmed-article:2055560 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:2055560 | lifeskim:mentions | umls-concept:C0011777 | lld:lifeskim |
| pubmed-article:2055560 | lifeskim:mentions | umls-concept:C0015133 | lld:lifeskim |
| pubmed-article:2055560 | lifeskim:mentions | umls-concept:C0026259 | lld:lifeskim |
| pubmed-article:2055560 | lifeskim:mentions | umls-concept:C0332325 | lld:lifeskim |
| pubmed-article:2055560 | lifeskim:mentions | umls-concept:C0442967 | lld:lifeskim |
| pubmed-article:2055560 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:2055560 | pubmed:dateCreated | 1991-8-1 | lld:pubmed |
| pubmed-article:2055560 | pubmed:abstractText | An effective second-line treatment for intermediate and high grade non-Hodgkin's lymphoma is greatly needed since 30% of patients do not achieved complete remission (CR) and another 20% to 30% of the CRs will eventually relapse. | lld:pubmed |
| pubmed-article:2055560 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2055560 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2055560 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2055560 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2055560 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2055560 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2055560 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2055560 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2055560 | pubmed:issn | 0390-6078 | lld:pubmed |
| pubmed-article:2055560 | pubmed:author | pubmed-author:GallaminiAA | lld:pubmed |
| pubmed-article:2055560 | pubmed:author | pubmed-author:BertiniMM | lld:pubmed |
| pubmed-article:2055560 | pubmed:author | pubmed-author:GhioRR | lld:pubmed |
| pubmed-article:2055560 | pubmed:author | pubmed-author:LevinDD | lld:pubmed |
| pubmed-article:2055560 | pubmed:author | pubmed-author:ResegottiLL | lld:pubmed |
| pubmed-article:2055560 | pubmed:author | pubmed-author:CavalleriMM | lld:pubmed |
| pubmed-article:2055560 | pubmed:author | pubmed-author:VitoloUU | lld:pubmed |
| pubmed-article:2055560 | pubmed:author | pubmed-author:OrsucciLL | lld:pubmed |
| pubmed-article:2055560 | pubmed:author | pubmed-author:Rota-Scalabri... | lld:pubmed |
| pubmed-article:2055560 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2055560 | pubmed:volume | 76 | lld:pubmed |
| pubmed-article:2055560 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2055560 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2055560 | pubmed:pagination | 43-6 | lld:pubmed |
| pubmed-article:2055560 | pubmed:dateRevised | 2010-3-24 | lld:pubmed |
| pubmed-article:2055560 | pubmed:meshHeading | pubmed-meshheading:2055560-... | lld:pubmed |
| pubmed-article:2055560 | pubmed:meshHeading | pubmed-meshheading:2055560-... | lld:pubmed |
| pubmed-article:2055560 | pubmed:meshHeading | pubmed-meshheading:2055560-... | lld:pubmed |
| pubmed-article:2055560 | pubmed:meshHeading | pubmed-meshheading:2055560-... | lld:pubmed |
| pubmed-article:2055560 | pubmed:meshHeading | pubmed-meshheading:2055560-... | lld:pubmed |
| pubmed-article:2055560 | pubmed:meshHeading | pubmed-meshheading:2055560-... | lld:pubmed |
| pubmed-article:2055560 | pubmed:meshHeading | pubmed-meshheading:2055560-... | lld:pubmed |
| pubmed-article:2055560 | pubmed:meshHeading | pubmed-meshheading:2055560-... | lld:pubmed |
| pubmed-article:2055560 | pubmed:meshHeading | pubmed-meshheading:2055560-... | lld:pubmed |
| pubmed-article:2055560 | pubmed:meshHeading | pubmed-meshheading:2055560-... | lld:pubmed |
| pubmed-article:2055560 | pubmed:meshHeading | pubmed-meshheading:2055560-... | lld:pubmed |
| pubmed-article:2055560 | pubmed:meshHeading | pubmed-meshheading:2055560-... | lld:pubmed |
| pubmed-article:2055560 | pubmed:meshHeading | pubmed-meshheading:2055560-... | lld:pubmed |
| pubmed-article:2055560 | pubmed:meshHeading | pubmed-meshheading:2055560-... | lld:pubmed |
| pubmed-article:2055560 | pubmed:articleTitle | Mitoxantrone, etoposide, cisplatin and dexamethasone (MEPD) as salvage chemotherapy in resistant non-Hodgkin's lymphoma. | lld:pubmed |
| pubmed-article:2055560 | pubmed:affiliation | Divisione di Ematologia, Ospedale Molinette, Torino, Italy. | lld:pubmed |
| pubmed-article:2055560 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2055560 | pubmed:publicationType | Clinical Trial | lld:pubmed |
